Key result
COVID-19 patients with prior heart disease face higher mortality, while COVID-19 therapies carry proarrhythmic risks.
Why the study?
Cardiovascular complications and heart rhythm disorders caused by COVID-19 and their pathophysiology require characterization due to their impact on mortality.
This review highlights that COVID-19 patients with pre-existing heart disease face higher mortality and that COVID-19 treatments may have proarrhythmogenic effects.
CV complications in COVID-19 warrant close monitoring; review leaves open optimal management strategies for prospective trials.
Currently the world population is besieged by COVID-19, a disease caused by the SARS-CoV-2 coronavirus; and it has been declared by the WHO as a pandemic. COVID-19 disease usually presents with mild respiratory symptoms, some patients have pneumonia, and in severe cases, acute respiratory distress syndrome (ARDS) and shock are seen. Cardiovascular complications in the course of COVID-19 are responsible for high mortality. A bibliographic review was carried out in order to characterize the pathophysiology of heart rhythm disorders caused by COVID-19 and its complications. A total of 22 bibliographic references were reviewed between books, medical journals and web pages of the Scielo and Infomed platforms. It is evident that those who suffer from previous heart disease are at risk of decompensation and have higher mortality. The drugs used during the treatment of this condition confer a proarrhythmogenic effect.
No takes yet. Share an insight, caveat, or question.
Rodríguez et al. (2025) conducted a review in COVID-19 and cardiac arrhythmias. COVID-19 and associated treatments was evaluated. COVID-19 patients with previous heart disease face higher mortality and decompensation risks, while drugs used for COVID-19 treatment confer a proarrhythmogenic effect.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: